Incidence of 106TBL Lymph Node Metastasis
A Prospective Observational Study of Left Tracheobronchial Lymph Node Metastasis in Patients With Esophageal Cancer
1 other identifier
observational
1,852
1 country
1
Brief Summary
the study was to document the incidence of left tracheobronchial lymph node metastasis, and the risk factors of metastasis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2025
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 21, 2025
CompletedFirst Submitted
Initial submission to the registry
September 3, 2025
CompletedFirst Posted
Study publicly available on registry
September 10, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 21, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 21, 2030
September 10, 2025
September 1, 2025
2 years
September 3, 2025
September 3, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of left tracheobronchial lymph node metastasis
number of patients who had left tracheobronchial lymph node metastasis/number of patients who had resection of left tracheobronchial lymph node
2 years
Secondary Outcomes (2)
Risk factors of left tracheobronchial lymph node metastasis
2 years
Survival of patients with left tracheobronchial lymph node metastasis
5 years
Study Arms (1)
prospective observation cohort
All patients who had surgery due to esophageal cancer with curative intent, no intervention was applied.
Interventions
no intervention was applied in this cohort
Eligibility Criteria
observation study population
You may qualify if:
- patients with esophageal squamous cell carcinoma
- clinical staging: cT1-4a N0/+ M0.
- no history of other malignancy.
You may not qualify if:
- esophageal cancer in the neck
- poor physical status to have esophagectomy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Fudan Universitylead
Study Sites (1)
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director, Institute of Thoracic Oncology, Fudan University
Study Record Dates
First Submitted
September 3, 2025
First Posted
September 10, 2025
Study Start
July 21, 2025
Primary Completion (Estimated)
July 21, 2027
Study Completion (Estimated)
July 21, 2030
Last Updated
September 10, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- the IPD and supporting information will be available from January 1st 2027 to December 31st 2030.
incidence, risk factors and survival data could be shared.